MassMutual Private Wealth & Trust FSB Sells 782 Shares of Elevance Health, Inc. (NYSE:ELV)

MassMutual Private Wealth & Trust FSB lowered its holdings in Elevance Health, Inc. (NYSE:ELV) by 53.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 694 shares of the company’s stock after selling 782 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Elevance Health were worth $256,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ELV. Raelipskie Partnership bought a new stake in shares of Elevance Health in the third quarter valued at approximately $26,000. PSI Advisors LLC bought a new stake in shares of Elevance Health during the 3rd quarter valued at $27,000. Eastern Bank bought a new stake in shares of Elevance Health during the 3rd quarter valued at $31,000. Dunhill Financial LLC grew its holdings in shares of Elevance Health by 57.8% during the 3rd quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock worth $37,000 after purchasing an additional 26 shares in the last quarter. Finally, Peterson Financial Group Inc. bought a new position in shares of Elevance Health in the third quarter worth $44,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ELV shares. Morgan Stanley cut their price objective on shares of Elevance Health from $643.00 to $551.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. TD Cowen cut their price target on shares of Elevance Health from $589.00 to $484.00 and set a “buy” rating for the company in a report on Monday, October 21st. Mizuho decreased their price objective on shares of Elevance Health from $585.00 to $505.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Raymond James set a $485.00 target price on Elevance Health in a research note on Friday, October 18th. Finally, UBS Group decreased their price target on Elevance Health from $605.00 to $555.00 and set a “buy” rating on the stock in a research note on Friday, October 18th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $524.87.

Elevance Health Stock Up 0.3 %

NYSE:ELV opened at $390.21 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.50 and a quick ratio of 1.50. Elevance Health, Inc. has a one year low of $362.21 and a one year high of $567.26. The firm’s 50 day simple moving average is $386.73 and its 200 day simple moving average is $464.16. The company has a market cap of $90.50 billion, a PE ratio of 14.23, a P/E/G ratio of 1.09 and a beta of 0.84.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.